"It is said that form follows function, but we see here that is not always true," said Akira Kaji, PhD, from Penn's Department of Microbiology. "The L-shaped structure of both RRF and tRNA may have more to do with the spatial constraints of maneuvering within the folds of the ribosome than their actual tasks."
The actual task of the ribosome recycling factor has been something of a mystery for researchers. Until recently, science was unaware of its role in the process of creating proteins – and its potential as a target for new antibiotics.
Protein manufacture is a fundamental process of life that has been understood better in concept than in mechanics. While the DNA may encode the blueprints used to create proteins, it is the ribosome – an organelle within the cell – that actually builds a new protein.
There are three steps that are generally considered part of the scientific dogma surrounding the creation of new proteins: Initiation (the start of building a protein from messenger RNA that has been transcribed from DNA); Elongation (adding new amino acids to chain that becomes the protein via tRNA); and Termination (capping the amino acid chain off, so that it can be folded into a protein).
"There is one more crucial step that we had missed for a long time: recycling," said Kaji. It is the step where the machinery of the protein synthesis is "recycled" so that they can be used for the next round of protein synthesis. This step does not happen by magic, and we have to ask – How do you disassemble the complex of the protein synthesis machinery so that they can be used again for the next round of translation?
According to Kaji and his colleagues, RRF binds to different locations within the ribosomal complex at different times. It seems that, if the ribosome is the protein factory, the RRF is the foreman, moving from location to location to 'supervise' the end of the assembly line. When the new protein is completed, RRF works in conjunction with other proteins to disassemble the ribosomal complex so that the components of the machinery are ready for the next round of protein creation.
Kaji believes that, since RRF plays the key role only in bacteria and mitochondria, the bacterial protein also provides an interesting target for new types of anti-bacterial agents. His research has already shown in the laboratory that bacteria lacking RRF cannot exist because of their inability to create new proteins.
"As bacteria mutate to become resistant to antibiotics, we must keep targeting parts of bacteria that are integral for functioning so that bacteria can not out-evolve antibiotics," said Kaji. "We are considering RRF as the target of a new type of antibiotic, an inhibitor of RRF that we can easily alter as bacteria become resistant."
Other scientists contributing to the research presented in Cell include Michael C. Kiel of Penn and Laura Lancaster and Harry F. Noller of the University of California at Santa Cruz.
Journal
Cell